Amgen (AMGN) Short-term Investments (2009 - 2023)

Amgen's Short-term Investments history runs 15 years deep, the most recent figure standing at $1.0 million for Q1 2023.

• In Q1 2023, Short-term Investments fell 93.75% year-over-year to $1.0 million; the TTM figure through Mar 2023 stood at $1.0 million (down 93.75% YoY), while the FY2022 annual figure was $1.7 billion, up 3391.67% from the prior year.
• Short-term Investments was $1.0 million for Q1 2023 at Amgen, down from $1.7 billion in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $18.9 billion in Q1 2019 to a low of $1.0 million in Q1 2023.
• Historically, Short-term Investments has averaged $4.1 billion across 5 years, with a median of $2.0 billion in 2022.
• Biggest YoY gain for Short-term Investments was 3391.67% in 2022; the steepest drop was 99.64% in 2022.
• A 5-year view of Short-term Investments shows it stood at $2.9 billion in 2019, then soared by 52.44% to $4.4 billion in 2020, then plunged by 98.9% to $48.0 million in 2021, then surged by 3391.67% to $1.7 billion in 2022, then tumbled by 99.94% to $1.0 million in 2023.
• The last three Short-term Investments figures came in at $1.0 million (Q1 2023), $1.7 billion (Q4 2022), and $2.0 billion (Q3 2022), per Business Quant data.